NO345476B1 - Bindingsproteiner for hepatocyttvekstfaktor (HGF) - Google Patents

Bindingsproteiner for hepatocyttvekstfaktor (HGF)

Info

Publication number
NO345476B1
NO345476B1 NO20085421A NO20085421A NO345476B1 NO 345476 B1 NO345476 B1 NO 345476B1 NO 20085421 A NO20085421 A NO 20085421A NO 20085421 A NO20085421 A NO 20085421A NO 345476 B1 NO345476 B1 NO 345476B1
Authority
NO
Norway
Prior art keywords
seq
variable region
amino acid
acid sequence
heavy chain
Prior art date
Application number
NO20085421A
Other languages
English (en)
Norwegian (no)
Other versions
NO20085421L (no
Inventor
May Han
S Kirk Wright
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
William M Winston
Arnold Horwitz
Original Assignee
Xoma Technology Ltd
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd, Aveo Pharmaceuticals Inc filed Critical Xoma Technology Ltd
Publication of NO20085421L publication Critical patent/NO20085421L/no
Publication of NO345476B1 publication Critical patent/NO345476B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
NO20085421A 2006-06-02 2007-06-01 Bindingsproteiner for hepatocyttvekstfaktor (HGF) NO345476B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (2)

Publication Number Publication Date
NO20085421L NO20085421L (no) 2009-02-27
NO345476B1 true NO345476B1 (no) 2021-02-22

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085421A NO345476B1 (no) 2006-06-02 2007-06-01 Bindingsproteiner for hepatocyttvekstfaktor (HGF)

Country Status (20)

Country Link
US (5) US7649083B2 (https=)
EP (2) EP2027156B9 (https=)
JP (3) JP4686634B2 (https=)
KR (1) KR101196060B1 (https=)
AR (1) AR061171A1 (https=)
AT (1) ATE495195T1 (https=)
AU (1) AU2007254942B2 (https=)
BR (1) BRPI0712222B1 (https=)
CA (1) CA2654025C (https=)
CY (1) CY1111714T1 (https=)
DE (1) DE602007011923D1 (https=)
DK (1) DK2027156T3 (https=)
IL (2) IL195037A (https=)
MX (1) MX2008014829A (https=)
NO (1) NO345476B1 (https=)
NZ (1) NZ573818A (https=)
PL (1) PL2027156T3 (https=)
PT (1) PT2027156E (https=)
SG (1) SG158112A1 (https=)
WO (1) WO2007143090A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) * 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
PT2271670E (pt) * 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
MX2013002084A (es) 2010-08-31 2013-05-09 Genentech Inc Biomarcadores y metodos de tratamiento.
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
SG11201400724SA (en) 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
US9181333B2 (en) 2012-07-13 2015-11-10 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2015301538A1 (en) * 2014-08-15 2017-03-02 Oncomed Pharmaceuticals, Inc. RSPO1 binding agents and uses thereof
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
AU2020327537A1 (en) 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
CA3191184A1 (en) * 2020-08-28 2022-03-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Signal peptide for reducing end heterogeneity of heterologous polypeptide
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017107A2 (en) * 2003-07-18 2005-02-24 Amgen Inc. Specific binding agents to hepatocyte growth factor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CA2607699A1 (en) * 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017107A2 (en) * 2003-07-18 2005-02-24 Amgen Inc. Specific binding agents to hepatocyte growth factor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS T. ET AL. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006, vol. 66, no. 3, side 1721-1729., Dated: 01.01.0001 *
BURR A. ET AL. Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration. J Pathol. 1998, vol. 185, no. 3, side 298-302., Dated: 01.01.0001 *
KIM KJ. ET AL. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res. 2006, vol. 12, no. 4, side 1292-1298., Dated: 01.01.0001 *
ZACCOLO M. ET AL. Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells. Eur J Immunol. 1997, vol. 27, no. 3, side 618-623., Dated: 01.01.0001 *

Also Published As

Publication number Publication date
AU2007254942A1 (en) 2007-12-13
CA2654025C (en) 2016-08-02
BRPI0712222B1 (pt) 2021-10-13
US20100173362A1 (en) 2010-07-08
JP2009539347A (ja) 2009-11-19
DE602007011923D1 (de) 2011-02-24
IL195037A0 (en) 2011-08-01
PT2027156E (pt) 2011-04-18
HK1129395A1 (en) 2009-11-27
BRPI0712222A2 (pt) 2012-01-10
IL195037A (en) 2015-08-31
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
US20080108565A1 (en) 2008-05-08
DK2027156T3 (da) 2011-04-26
JP2011072318A (ja) 2011-04-14
IL219654A0 (en) 2012-06-28
ATE495195T1 (de) 2011-01-15
US7649083B2 (en) 2010-01-19
US8580930B2 (en) 2013-11-12
US20130203963A1 (en) 2013-08-08
EP2027156B9 (en) 2011-03-30
NZ573818A (en) 2011-09-30
JP2013090632A (ja) 2013-05-16
CY1111714T1 (el) 2015-10-07
PL2027156T3 (pl) 2011-06-30
AU2007254942B2 (en) 2011-10-27
US7943344B2 (en) 2011-05-17
US20140178935A1 (en) 2014-06-26
KR20090027226A (ko) 2009-03-16
JP5735476B2 (ja) 2015-06-17
EP2027156A2 (en) 2009-02-25
EP2361934A3 (en) 2011-11-02
CA2654025A1 (en) 2007-12-13
NO20085421L (no) 2009-02-27
EP2027156B1 (en) 2011-01-12
MX2008014829A (es) 2009-01-29
AU2007254942A8 (en) 2009-02-05
WO2007143090A3 (en) 2008-03-13
KR101196060B1 (ko) 2012-11-01
JP4686634B2 (ja) 2011-05-25
US8273355B2 (en) 2012-09-25
US20110229462A1 (en) 2011-09-22
EP2361934A2 (en) 2011-08-31
US9096664B2 (en) 2015-08-04
WO2007143090A2 (en) 2007-12-13
SG158112A1 (en) 2010-01-29

Similar Documents

Publication Publication Date Title
US8575318B2 (en) Hepatocyte growth factor (HGF) binding proteins
US9096664B2 (en) Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins
CN110023338A (zh) 用于与抗pd-l1抗体组合的抗tim-3抗体
CN101460520B (zh) 肝细胞生长因子(hgf)的结合蛋白质
MX2007013756A (en) Sclerostin epitopes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application